Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019 : a systematic analysis from the Global Burden of Disease Study 2019

Background Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally. Methods We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available. Findings Globally in 2019, 1.14 billion (95% uncertainty interval 1.13-1.16) individuals were current smokers, who consumed 7.41 trillion (7.11-7.74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27.5% [26. 5-28.5] reduction) and females (37.7% [35.4-39.9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0.99 billion (0.98-1.00) in 1990. Globally in 2019, smoking tobacco use accounted for 7.69 million (7.16-8.20) deaths and 200 million (185-214) disability-adjusted life-years, and was the leading risk factor for death among males (20.2% [19.3-21.1] of male deaths). 6.68 million [86.9%] of 7.69 million deaths attributable to smoking tobacco use were among current smokers. Interpretation In the absence of intervention, the annual toll of 7.69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a dear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019

Background Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally. Methods We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available. Findings Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking tobacco use were among current smokers. Interpretation In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens. Funding Bloomberg Philanthropies and the Bill & Melinda Gates Foundation

Fascial space infection patients reporting to Department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot: A retrospective study

Aim: This aim of this study is being conducted to assess the incidence of fascial space infection and its management in patients presenting to department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot. Methods: This retrospective study was done the in the Department of Oral and Maxillofacial Surgery Dasmesh Institute of Research and Dental Sciences, Faridkot, India, from January 2015 to December 2020. Total 84 fascial space infection record of previous five year patients (reporting to Department of Oral and Maxillofacial Surgery was evaluated. Patients reported with fascial space infection with age group from 16-70 yrs and ASA I & I were included in this study. Results: The age group most commonly involved was in the third and fourth decades of life. The mean age group was 33.55. Males (55.95%) were more commonly involved than females (44.05%)

Fascial space infection patients reporting to department of oral and maxillofacial surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot: A retrospective study

This aim of this study is being conducted to assess the incidence of fascial space infection and its management in patients presenting to department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot. This retrospective study was done the in the Department of Oral and Maxillofacial Surgery Dasmesh Institute of Research and Dental Sciences, Faridkot, India, from January 2015 to December 2020. Total 84 fascial space infection record of previous five year patients (reporting to Department of Oral and Maxillofacial Surgery was evaluated. Patients reported with fascial space infection with age group from 16-70 yrs and ASA I & I were included in this study. The age group most commonly involved was in the third and fourth decades of life. The mean age group was 33.55. Males (55.95%) were more commonly involved than females (44.05%). The most commonly involved space was Right submandibular space infection (17.86%) followed by left submandibular space infection 15.48, R buccal space infection (9.52%), Left buccal space infection (7.14%), Right infraorbital space infection (7.14%), Left pterygomandibular space infection (7.14%),Space infection wrt left submandibular space, submental space, left sublingual space(5.95%), Masticatory space infection with impending submandibular + submental cellulitis (5.95%)

Fascial Space Infection Patients Reporting to Department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot: A Retrospective Study

This aim of this study is being conducted to assess the incidence of Fascial space infection and its management in patients presenting to department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot. This retrospective study was done the in the Department of Oral and Maxillofacial Surgery Dasmesh Institute of Research and Dental Sciences, Faridkot, India, from January 2015 to December 2020. Total 84 Fascial space infection record of previous five year patients (reporting to Department of Oral and Maxillofacial Surgery was evaluated. Patients reported with Fascial space infection with age group from 16-70 yrs and ASA I & I were included in this study. The age group most commonly involved was in the third and fourth decades of life. The mean age group was 33.55. Males (55.95%) were more commonly involved than females (44.05%). The most commonly involved space was Right submandibular space infection (17.86%) followed by left submandibular space infection 15.48, R buccal space infection (9.52%), Left buccal space infection (7.14%), Right infraorbital space infection (7.14%), Left pterygomandibular space infection (7.14%),Space infection wrt left submandibular space, submental space, left sublingual space(5.95%), Masticatory space infection with impending submandibular + submental cellulitis (5.95%)

Fascial Space Infection Patients Reporting to Department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot: A Retrospective Study

Aim: This aim of this study is being conducted to assess the incidence of Fascial space infection and its management in patients presenting to department of Oral and Maxillofacial Surgery at Dasmesh Institute of Research and Dental Sciences, Faridkot. Methods: This retrospective study was done the in the Department of Oral and Maxillofacial Surgery Dasmesh Institute of Research and Dental Sciences, Faridkot, India, from January 2015 to December 2020. Total 84 Fascial space infection record of previous five year patients (reporting to Department of Oral and Maxillofacial Surgery was evaluated. Patients reported with Fascial space infection with age group from 16-70 yrs and ASA I & I were included in this study. Results: The age group most commonly involved was in the third and fourth decades of life. The mean age group was 33.55. Males (55.95%) were more commonly involved than females (44.05%)

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

Background: Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally. Methods: We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available. Findings: Globally in 2019, 1·14 billion (95% uncertainty interval 1·13–1·16) individuals were current smokers, who consumed 7·41 trillion (7·11–7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5% [26·5–28·5] reduction) and females (37·7% [35·4–39·9] reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98–1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16–8·20) deaths and 200 million (185–214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% [19·3–21·1] of male deaths). 6·68 million [86·9%] of 7·69 million deaths attributable to smoking tobacco use were among current smokers. Interpretation: In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens. Funding: Bloomberg Philanthropies and the Bill & Melinda Gates Foundation

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990�2019: a systematic analysis from the Global Burden of Disease Study 2019

Background: Ending the global tobacco epidemic is a defining challenge in global health. Timely and comprehensive estimates of the prevalence of smoking tobacco use and attributable disease burden are needed to guide tobacco control efforts nationally and globally. Methods: We estimated the prevalence of smoking tobacco use and attributable disease burden for 204 countries and territories, by age and sex, from 1990 to 2019 as part of the Global Burden of Diseases, Injuries, and Risk Factors Study. We modelled multiple smoking-related indicators from 3625 nationally representative surveys. We completed systematic reviews and did Bayesian meta-regressions for 36 causally linked health outcomes to estimate non-linear dose-response risk curves for current and former smokers. We used a direct estimation approach to estimate attributable burden, providing more comprehensive estimates of the health effects of smoking than previously available. Findings: Globally in 2019, 1·14 billion (95 uncertainty interval 1·13�1·16) individuals were current smokers, who consumed 7·41 trillion (7·11�7·74) cigarette-equivalents of tobacco in 2019. Although prevalence of smoking had decreased significantly since 1990 among both males (27·5 26·5�28·5 reduction) and females (37·7% 35·4�39·9 reduction) aged 15 years and older, population growth has led to a significant increase in the total number of smokers from 0·99 billion (0·98�1·00) in 1990. Globally in 2019, smoking tobacco use accounted for 7·69 million (7·16�8·20) deaths and 200 million (185�214) disability-adjusted life-years, and was the leading risk factor for death among males (20·2% 19·3�21·1 of male deaths). 6·68 million 86·9% of 7·69 million deaths attributable to smoking tobacco use were among current smokers. Interpretation: In the absence of intervention, the annual toll of 7·69 million deaths and 200 million disability-adjusted life-years attributable to smoking will increase over the coming decades. Substantial progress in reducing the prevalence of smoking tobacco use has been observed in countries from all regions and at all stages of development, but a large implementation gap remains for tobacco control. Countries have a clear and urgent opportunity to pass strong, evidence-based policies to accelerate reductions in the prevalence of smoking and reap massive health benefits for their citizens. Funding: Bloomberg Philanthropies and the Bill & Melinda Gates Foundation. © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licens

Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019

10.1016/s0140-6736(21)01169-7The Lancet397102922337-236